The gold standard to count circulating hematopoietic stem and progenitor cells (HPCs) is to enumerate CD34 + cells by using flow cytometry [1, 2] . XE-2100 (Sysmex, Kobe, Japan), a currently used hematology analyzer, can be used to quantify HPCs, generating counts that reportedly correlate with those obtained using flow cytometric analysis of CD34 + cells; however, XE-2100 HPC counts were 1.86-fold higher than those calculated by flow cytometry [3] . The recently launched XN-2000 (Sysmex) can also be used to quantify HPCs, but its performance on HPC counts has not been evaluated. We assessed the HPC counting performance of XE-2100 and XN-2000 and compared them to HPC count-related parameters for 120 samples obtained using the two automated blood cell analyzers were compared. XN-2000 HPC numbers were significantly lower than those obtained using XE-2100 (0.005 × 10 9 /L vs. 0.007 × 10 9 /L, P < 0.001). The regression analysis of XE-2100 HPC and CD34 + cell proportion (%) showed poor correlation (γ = 0.187). In contrast, the proportion (%) of XN-2000 HPCs yielded correlations that were significantly improved (γ = 0.590). XE-2100 HPC and CD34 + cell proportion (%) showed a mean bias of 0.2%, suggesting that HPC proportion (%) measured using XE-2100 is overestimated by a mean of 0.2% when compared to those measured using flow cytometry (Fig. 1A) . In contrast, HPC proportion (%) measured using XN-2000 produced an improved mean bias of 0.0% (Fig. 1B) . Subsequent analysis of HPC numbers confirmed that XN-2000 showed improved performance over XE-2100. The regression analysis between HPC numbers measured using the two automated blood cell analyzers and CD34 + cell numbers showed that XN-2000 had improved correlation (γ = 0.652) compared to XE-2100 (γ = 0.548). The analysis also showed that bias was reduced when XN-2000 was used instead of XE- 
